SUMMARY
INTRODUCTION
Measles is a highly contagious airborne disease and remains a major cause of morbidity and mortality despite the availability of an effective vaccine (WHO, 2012) . The causative agent, measles virus (MV), severely suppresses immune responses in the host, leading to secondary opportunistic infections (Moss and Griffin, 2012) . Production of antiviral type I interferon (IFN) is important for the control of MV replication and hence disease progression. Therefore, MV has evolved various strategies to suppress type I IFN responses, most of which rely on the nonstrucural MV-V protein that can antagonize activation of pattern recognition receptors (PRRs) or signaling upstream of type I IFN responses (Fontana et al., 2008; Goodbourn and Randall, 2009) .
Type I IFN responses induced by single-stranded RNA (ssRNA) viruses, such as MV, are mediated by the cytoplasmic RIG-I-like receptors (RLRs) RIG-I and Mda5. RIG-I interacts with the 5 0 leader of MV ssRNA to induce IFN-b (Plumet et al., 2007) . The mechanisms leading to Mda5 activation by MV are still unknown (Ikegame et al., 2010) . RLR triggering leads to activation of IkB kinase (IKK)-related kinases, IKKε and Tank-binding protein (TBK1), through the mitochondrial antiviral signaling (MAVS; also known as IPS-1) adaptor protein (Fitzgerald et al., 2003; Sharma et al., 2003) . Both IKKε and TBK1 activate transcription factor IRF3, which induces expression of IFN-b (Kawai and Akira, 2008) . Signaling by IFN-b via type I IFN-a/b receptor (IFNAR) on infected and neighboring cells induces transcription of hundreds of interferon-stimulated genes (ISGs), such as MxA and ISG15, that are paramount in defense against viruses (Fontana et al., 2008) . RLR signaling pathways induce a very potent and rapid type I IFN response; therefore, activation of RLRs is tightly regulated by multiple consecutive processes, including dephosphorylation, ubiquitination, and oligomerization of the RLR CARD domains (Gack et al., 2007 Jiang et al., 2012; Nistal-Villá n et al., 2010; Wies et al., 2013; Zeng et al., 2010) . Constitutive phosphorylation of CARD domain residues Ser8 and Thr170 of RIG-I and Ser88 of Mda5 keeps RLRs inactive Nistal-Villá n et al., 2010; Wies et al., 2013) . RLR-induced type I IFN production requires RLR dephosphorylation by serinethreonine phosphatases PP1a and PP1g (Wies et al., 2013) . The exact regulation of these phosphatases is not yet understood, but dephosphorylation of RIG-I and Mda5 is crucial for activation of MAVS and subsequent downstream signaling, possibly through induction of oligomerization Nistal-Villá n et al., 2010; Wallach and Kovalenko, 2013; Wies et al., 2013) .
Airborne infection of MV initiates in the lungs and disseminates to lymphocytes throughout the host within 2 weeks postinfection (de Swart et al., 2007; Lemon et al., 2011) . DC-SIGN + dendritic cells (DCs) in the lungs are among the first cells that become infected (Lemon et al., 2011; Mesman et al., 2012) and express signaling lymphocyte activation molecule (SLAM, CD150), the entry receptor for wild-type MV (de Swart et al., 2007; Tatsuo et al., 2000) . Interaction of MV with C-type lectin receptor DC-SIGN enhances infection of DCs and subsequent viral transmission to lymphocytes (de Witte et al., 2006 (de Witte et al., , 2008 Mesman et al., 2012) . DCs also induce MV-specific adaptive immunity; DC-SIGN sensing of MV induces innate signaling mediated by serine-threonine kinase Raf-1, which modulates Toll-like receptor (TLR)-induced immune responses (Gringhuis et al., 2007) . Raf-1 signaling induces phosphorylation and acetylation of TLR-induced NF-kB subunit p65, thereby increasing expression of proinflammatory cytokines affecting immune responses (Gringhuis et al., 2007 (Gringhuis et al., , 2009a . However, little is known about the role of innate signaling induced by MV on type I IFN responses in DCs. Here, we show that MV efficiently infects primary human DCs by inhibiting RLR-induced type I IFN responses. We demonstrate that GADD34 is the regulatory subunit of the PP1 phosphatases that activate both RIG-I and Mda5, while activity of GADD34-PP1 holoenzymes is regulated by PP1 inhibitor 1 (I-1). Notably, MV binding to DC-SIGN at the cell surface prevents dephosphorylation of both RIG-I and Mda5 by inhibiting GADD34-PP1 holoenzyme activation via Raf-1 signaling. Raf-1 activation induces phosphorylation of I-1, thereby inducing complex formation between I-1 and GADD34-PP1 holoenzymes, which inhibits its phosphatase activity. Inhibition of dephosphorylation of both RIG-I and Mda5 suppresses type I IFN responses in DCs upon MV infection. Interference with DC-SIGN signaling allows dephosphorylation of both RLRs, leading to strong antiviral type I IFN responses that suppress MV replication. Triggering of innate signaling by MV to circumvent cellular antiviral mechanisms precedes viral evasion tactics that rely on viral replication and de novo synthesis of viral proteins, hence acting earlier during infection. Thus, we have uncovered a regulatory mechanism that controls RLR activation and identified the phosphatase inhibitor I-1 as a target for suppression of antiviral responses, which is exploited by MV to infect DCs. This evasion mechanism might be used by other viruses and targeted therapeutically for more efficient combating of viral infections.
RESULTS

MV Infection of DCs Requires Both CD150 and DC-SIGN
To investigate the function of viral receptors involved in replication of MV, human monocyte-derived DCs were infected with pathogenic strain rMV KS EGFP(3) (rMV KS ) in the presence of blocking antibodies against CD150 and DC-SIGN. This virulent recombinant strain expresses enhanced GFP (EGFP) as a result of viral replication, without altering its pathogenicity (de Swart et al., 2007; de Vries et al., 2012; Lemon et al., 2011; Ludlow et al., 2013) . DCs were efficiently infected with the virus as measured by flow cytometry 24 hr postinfection (h.p.i.). CD150 was crucial for infection since blocking antibodies against CD150 almost completely abrogated infection, whereas blocking DC-SIGN binding decreased infection ( Figure 1A ). Analysis of GFP expression in infected cells, as a measure for replication, showed that CD150 blocking antibodies did not alter the replication level of MV in DCs, despite the large effect on the percent of infected cells ( Figure 1B) . Notably, blocking DC-SIGN binding decreased MV infection as well as replication in DCs (Figures 1A and 1B) , suggesting that DC-SIGN signaling affects not only fusion but also the replication cycle of MV. We next determined viral transcription over time after infection of DCs. MV-N is the first transcribed gene of the unsegmented MV genome upon cellular entry (Rima and Duprex, 2009 ). We detected MV-N mRNA as early as 2 h.p.i., accumulating over time, while viral transcription was strongly decreased with blocking antibodies against both CD150 and DC-SIGN ( Figure 1C ). These data indicate that both CD150 and DC-SIGN are important for early transcription; however, whereas CD150 is required for infection, MV binding to DC-SIGN is critical for both infection and replication. (Figure 2C) . Notably, DC infection was enhanced when either RIG-I or Mda5 was silenced ( Figure 2D ), strongly indicating that type I IFN responses to MV limit MV replication. Transfection of DCs with RLR ligand poly(I:C)-LyoVec (poly(I:C)-LV) induced type I IFN responses, which were abrogated by silencing of either receptor ( Figure 2E ), supporting specificity of RLR silencing. RLR signaling through adaptor protein MAVS induces activation of TBK1 and IKKε through phosphorylation at specific sites (Fitzgerald et al., 2003; Sharma et al., 2003) . Silencing of either TBK1 or IKKε ( Figure S1 ) reduced MV-induced IFN-b, MxA, and ISG15 expression, whereas combined silencing of TBK1 and IKKε almost completely abrogated MV-induced type I IFN responses in DCs ( Figure 2F ). These data demonstrate that MV-induced antiviral type I IFN responses in DCs are triggered via both RIG-I and Mda5 and depend on TBK1-IKKε signaling. antibody crosslinking ( Figure 3A ). To investigate whether DC-SIGN-mediated suppression of RLR-induced type I IFN responses was dependent on Raf-1 signaling (Gringhuis et al., 2007) , we blocked Raf-1 activity via small molecule inhibitor GW5074 (Lackey et al., 2000) or Raf-1 silencing ( Figure 3B ). Blocking Raf-1 signaling reversed DC-SIGN-mediated suppression of poly(I:C)-LV-induced IFN-b, MxA, and ISG15 mRNA expression ( Figures 3A and 3C ). Thus, DC-SIGN signaling suppresses RLR-induced type I IFN responses via Raf-1 activation. DC-SIGN triggering with various pathogen ligands activates Raf-1 through phosphorylation of Ser338 and Tyr340-Tyr341 (Gringhuis et al., 2007 (Gringhuis et al., , 2009a . Similarly, crosslinking of DC-SIGN with specific DC-SIGN antibodies, in contrast to isotype controls, led to Raf-1 phosphorylation at both Ser338 and Tyr340-Tyr341 ( Figure 3D ). Notably, DC infection with rMV KS also led to phosphorylation of Raf-1, in a DC-SIGN-dependent manner ( Figure 3E ). We next investigated whether Raf-1 signaling via DC-SIGN is involved in MV-mediated suppression of type I IFN responses. Notably, inhibition of Raf-1 by either GW5074 or Raf-1 silencing increased MV-mediated IFN-b, MxA, and ISG15 expression in response to infection with rMV KS ( Figures 3F and 3G ). These data demonstrate that DC-SIGN signaling suppresses RLR-induced type I IFN responses via Raf-1, while MV uses this mechanism to impair type I IFN production in DCs.
RIG-I and
MV Suppresses Type I IFN Responses via DC-SIGN
DC-SIGN Signaling via Raf-1 Suppresses RLR Activation
Constitutive phosphorylation of the CARD domains of RIG-I and Mda5 keeps the receptors in their inactive state. Therefore, activation requires dephosphorylation of RIG-I at Ser8 and Thr170, and Mda5 at Ser88 Nistal-Villá n et al., 2010; Wies et al., 2013) . We next investigated whether DC-SIGN/Raf-1 signaling affects phosphorylation of RIG-I and Mda5. First, we observed that DC-SIGN crosslinking prevented poly(I:C)-LV-induced dephosphorylation of RIG-I and Mda5 ( Figure 4A ). Moreover, Raf-1 inhibition restored dephosphorylation of both receptors ( Figure 4B ). These data indicate that DC-SIGN signaling suppresses RLR activation via Raf-1 by preventing dephosphorylation of their CARD domains. Strikingly, infection with rMV KS did not result in dephosphorylation of RIG-I and
Mda5 at 8 h.p.i., whereas inhibition or silencing of Raf-1 dramatically increased the MV-induced dephosphorylation of both receptors ( Figures 4C, 4D , and S2). Similarly, dephosphorylation of RIG-I and Mda5 was blocked in a Raf-1-dependent manner after infection of DCs with another pathogenic MV strain, rMV IC323 EGFP(1) (rMV IC323 ) (de Swart et al., 2007) , that also required DC-SIGN for infection and replication ( Figures 4C, 4D , and S3). These data show that MV-induced Raf-1 signaling suppresses RIG-I and Mda5 activation by preventing dephosphorylation. Notably, at 16 h.p.i., rMV KS induced dephosphorylation of RIG-I at Ser8 and Thr170, but not Mda5 at Ser88 (Figure 4C ), which could explain the increase in IFN-b and MxA levels between 8 and 24 h.p.i. (Figure 2A ). Raf-1 inhibition did not restore Mda5 dephosphorylation 16 hr after MV infection ( Figure 4C ), suggesting that, late during infection, Mda5 dephosphorylation is antagonized via another DC-SIGN-independent mechanism (Davis et al., 2014) . We next investigated the effect of DC-SIGN triggering on downstream RLR signaling. We observed that phosphorylation of TBK1 and IKKε at Ser172 in response to poly(I:C)-LV stimulation was impaired by simultaneous DC-SIGN triggering but was restored after Raf-1 inhibition (Figure 5A) . Moreover, infection of DCs with either rMV KS or rMV IC323 induced a small increase in TBK1 and IKKε phosphorylation at Ser172, which was strongly enhanced after inhibition of Raf-1 signaling ( Figure 5B ). Activation of TBK1 and IKKε precedes phosphorylation and nuclear translocation of IRF3, which (Kawai and Akira, 2008) . We observed that rMV KS infection led to minor nuclear accumulation of IRF3, while, again, Raf-1 inhibition strongly increased nuclear translocation of IRF3, allowing IFN-b production ( Figures 5C and  5D ). These results demonstrate that DC-SIGN-induced Raf-1 activation suppresses downstream RLR signaling by blocking the dephosphorylation of both RIG-I and Mda5.
Raf-1 Activation Blocks PP1 Activity to Attenuate RLR Activation Dephosphorylation of the CARD domains of RIG-I and Mda5 is mediated by PP1a/g phosphatases (Wies et al., 2013) ; however, little is known about the regulation of PP1 phosphatase activity.
To investigate whether DC-SIGN signaling interferes with the activity of these phosphatases, we measured PP1 phosphatase activity in lysates of DCs stimulated with poly(I:C)-LV in combination with DC-SIGN crosslinking or after infection with MV. Although DC-SIGN activation slightly decreased overall PP1 activity, no statistical differences between unstimulated and stimulated cells were observed ( Figure 6A ). PP1 phosphatases are ubiquitously expressed in cells, and PP1 holoenzymes consist of a catalytic and regulatory subunit, the latter of which determines substrate specificity (Cohen, 2002; Peti et al., 2013) . To specifically examine whether Raf-1 influences PP1a/g phosphatases, we set out to identify the regulatory subunit of the PP1 holoenzymes that control the dephosphorylation of RLRs. One of the possible PP1-binding partners, growth arrest and DNA damage protein (GADD34), has been reported to be required for IFNb responses after viral infection in DCs (Clavarino et al., 2012) .
We therefore investigated whether GADD34 association with the catalytic PP1a/g subunits is involved in dephosphorylation of RIG-I and Mda5. Pretreatment of DCs with the specific GADD34 inhibitor guanabenz (Tsaytler et al., 2011) blocked dephosphorylation of RIG-I at Ser8 and Thr170 and Mda5 at Ser88 in a concentration-dependent manner, indicative of the involvement of GADD34 in RLR activation ( Figure 6B ). We next assessed GADD34-PP1-specific activity in DCs following pull down of GADD34 from whole-cell lysates after poly(I:C)-LV stimulation or MV infection. We observed a strong increase in PP1 activity after poly(I:C)-LV stimulation, which was blocked by DC-SIGN triggering ( Figure 6C ). Inhibition of Raf-1 restored PP1 activity after poly(I:C)-LV plus DC-SIGN costimulation ( Figure 6C ). Notably, DC infection with either rMV KS or rMV
IC323
did not induce GADD34-PP1 activity; however, inhibition of Raf-1 resulted in a strong increase in phosphatase activity (Figure 6C) . These results strongly indicate that Raf-1 activation blocks PP1 activity in GADD34-PP1 complexes to prevent RLR activation. Activity of GADD34-PP1 complexes is specifically inhibited by I-1; association of I-1 with GADD34-PP1 blocks interactions between the holoenzymes and their substrates (Aggen et al., 2000) . Since I-1 requires phosphorylation at Thr35 and Ser67 for the association with GADD34-PP1 complexes (Connor et al., 2001; Huang and Paudel, 2000) , we examined whether Raf-1 modulates PP1 activity-and subsequent RLR activity-by phosphorylating I-1. First, we assessed phosphorylation of I-1 upon MV infection. I-1 became phosphorylated at both Ser and Thr residues in response to rMV KS , which coincided with its association with both PP1a and PP1g holoenzymes, as both catalytic subunits immunoprecipitated together with I-1 ( Figure 6D ). Both phosphorylation and association of I-1 with PP1a and PP1g was dependent on Raf-1 activity ( Figure 6D ). Next, we measured RLR phosphorylation levels in DCs after silencing I-1 ( Figure S1 ). Silencing of I-1 allowed dephosphorylation of both RIG-I and Mda5 after MV infection ( Figure 6E) . Similarly, I-1 silencing after costimulation with poly(I:C)-LV and DC-SIGN crosslinking allowed complete dephosphorylation of both RLRs to the same level as poly(I:C)-LV alone ( Figure 6F ). Together, these results show that Raf-1 signaling leads to phosphorylation of I-1 and subsequent association of I-1 with PP1 holoenzymes, which prevents RLR dephosphorylation and subsequent RLR activation. Moreover, silencing of GADD34 ( Figure S1 ) completely abolished RLR dephosphorylation after MV infection or poly(I:C)-LV stimulation ( Figures 6E and 6F ), confirming the role of GADD34-PP1 holoenzymes in mediating RLR dephosphorylation. We next investigated the functional effects of this signaling pathway on type I IFN expression. GADD34 silencing suppressed RLR-induced IFN-b and ISG induction after poly(I:C)-LV stimulation ( Figure 6G ), whereas I-1 silencing completely abrogated DC-SIGN-mediated suppression of IFN-b and ISG mRNA expression ( Figure 6G ). Moreover, rMV KS -induced IFN-b and ISG mRNA levels, which were reduced via Raf-1 signaling, strongly increased after I-1 silencing ( Figure 6H ). Together, these results indicate that DC-SIGN-induced Raf-1-mediated signaling induces association of I-1 with GADD34-PP1 holoenzymes to block PP1 activity and, subsequently, RLR dephosphorylation and RLR-mediated type I IFN responses to MV.
MV-Induced Raf-1 Activation Enables DC Infection
We next investigated whether DC-SIGN-induced inhibition of GADD34-PP1 holoenzyme activity was required for MV infection by silencing the regulatory subunit of PP1, GADD34, and the PP1 inhibitor I-1. Infection of DCs by MV was strongly increased by silencing of GADD34 ( Figure 7A ), suggesting that loss of type I IFN responses after GADD34 silencing ( Figure 6H ) allows efficient replication of MV in DCs. Notably, silencing of I-1, which is crucial in MV-induced type I IFN suppression, strongly decreased MV infection at both 24 and 48 hr after infection (Figure 7B) . Similarly, silencing of Raf-1 strongly decreased infection of MV in DCs ( Figure 7C ), which is in line with the observed increase of type I IFN responses ( Figures 3E and 3F ). We next examined whether MV infection of lung-resident DC-SIGN + DCs isolated from cynomolgus macaques was similarly dependent on Raf-1 activation. Inhibition of Raf-1 increased MV-mediated IFN-b and MxA expression in response to infection with rMV KS (Figure 7D ), while replication was attenuated ( Figure 7E ). These data demonstrate that inhibition of phosphatase activity and subsequent activation of RIG-I and Mda5 is an important mechanism for MV to escape antiviral responses. Furthermore, our data suggest that viruses such as MV target DC-SIGN to suppress type I IFN responses and thereby infect DCs.
DISCUSSION
Type I IFN responses are crucial in the elimination of viral infections, and therefore viruses have developed several strategies to manipulate these antiviral responses to escape immune surveillance. DC-SIGN + DCs are targeted by MV early in infection (Lemon et al., 2011; Mesman et al., 2012) , which makes them an important target for suppression of antiviral responses by the virus. Here we have elucidated the mechanism by which MV suppresses type I IFN responses in DCs early after infection, and we have identified DC-SIGN as an important suppressor of RLR activity. Although MV triggered type I IFN responses via RIG-I and Mda5, MV-induced DC-SIGN signaling via Raf-1 dampened RLR-elicited type I IFN expression. Raf-1 activation following DC-SIGN ligation resulted in phosphorylation of the inhibitory subunit I-1 at both Ser and Thr residues, thereby inducing association of I-1 to GADD34-PP1a/g phosphatases. As a result, GADD34-PP1 holoenzymes were inhibited and unable to dephosphorylate the RIG-I and Mda5 CARD domains, preventing signaling via MAVS to downstream effectors TBK1 and IKKε, IRF3, and subsequent type I IFN expression, hence promoting DC infection. Activation of innate signaling by MV to circumvent cellular antiviral mechanisms precedes other viral evasion tactics that rely on viral replication. In vivo relevance of this DC-SIGN mechanism was emphasized in lung DCs from nonhuman primates.
MV has been shown to trigger both RIG-I and Mda5 in cell lines (Shingai et al., 2007) , and here we show that MV triggers both RIG-I and Mda5 upon infection of DCs; however, their activation is counteracted by the interaction of MV with DC-SIGN, allowing efficient infection of DCs. Strikingly, we found that MV infection of DCs almost completely inhibited dephosphorylation of RIG-I residues Ser8 and Thr170 and Mda5 residue Ser88. Dephosphorylation of RIG-I at these residues has recently been described as one of the steps preventing unnecessary signal transduction to MAVS following ligand binding, since it allows accessibility to the CARD domains enabling MAVS interactions (Kolakofsky et al., 2012) . Dephosphorylation of these residues by serine-threonine phosphatases PP1a and PP1g is therefore a prerequisite for RLR activation Nistal-Villá n et al., 2010; Wies et al., 2013) . PP1 phosphatases are involved in many cellular processes, and their localization and actions are defined by specific regulatory and inhibitory subunits (Cohen, 2002; Peti et al., 2013) . Here we demonstrated that GADD34 is the regulatory subunit of PP1a/g holoenzymes that target RIG-I and Mda5 for dephosphorylation, and consequently are crucial for subsequent type I IFN induction. Moreover, GADD34-PP1 complexes were specifically inhibited by I-1. Activity of GADD34-PP1 holoenzymes limited MV replication in DCs by inducing type I IFN expression. Identification of PP1a/g regulatory subunit GADD34 and its specific inhibitor I-1 in the activation process of RIG-I and Mda5 in DCs further advances our knowledge of RLR receptor regulation.
Besides cytosolic RLRs, MV also triggered DC-SIGN signaling, leading to DC-SIGN-mediated Raf-1 activation. We found that MV-induced Raf-1 activation inhibited dephosphorylation of both RIG-I and Mda5, and thereby prevented RLR activation and subsequent antiviral responses. We identified the inhibitory subunit I-1 as a target for the kinase Raf-1. It remains to be established whether phosphorylation of I-1 occurs either directly by Raf-1 or via downstream effector(s). We observed that Raf-1-mediated phosphorylation of I-1 induced its association with GADD34-PP1-specific holoenzymes, which blocked the phosphatase activity of the GADD34-PP1 complexes and thereby prevented RLR activation. The inhibition of both RIG-I and Mda5 in DCs strongly suppressed type I IFN responses and allowed efficient replication of MV in DCs. Thus, these findings have identified PP1 phosphatases as targets for antiviral suppression. DC-SIGN-mediated suppression of RLR activation is crucial for MV to infect DCs, since Raf-1 inhibition by small molecule inhibitors or RNAi led to a strong increase of IFN-b and ISG expression after MV infection, which inhibited viral replication, underscoring the importance of DC-SIGN-dependent RLR suppressive mechanism in establishing MV replication in DCs. DC-SIGN crosslinking with antibodies against DC-SIGN similarly induced Raf-1 activation and suppressed RLR dephosphorylation, strongly suggesting that antibody crosslinking induces mannose-specific signaling by DC-SIGN (Gringhuis et al., 2009a) and can be used to investigate the role of mannose signaling via DC-SIGN in modulation of immune responses.
Further investigation revealed the transient nature of the DC-SIGN-mediated modulation of RLR signaling. Two pathogenic MV strains inhibited RLR dephosphorylation early after infection in a Raf-1-dependent manner. Our data strongly suggest that the Raf-1-dependent suppressive mechanism is the major mechanism early in infection for MV to establish infection of DCs, since Raf-1 inhibition strongly increased type I IFN responses and decreased MV infection. Notably, at 16 h.p.i, we observed that Mda5 remained phosphorylated, whereas RIG-I was dephosphorylated. These data suggest that another mechanism later during infection prevents Mda5, but not RIG-I dephosphorylation. MV nonstructural P/V/C proteins have been described to interfere with type I IFN induction, e.g., by interacting with RLRs or downstream effector molecules in RLR or interferon signaling pathways (Andrejeva et al., 2004; Palosaari et al., 2003; Ramachandran and Horvath, 2009; Schuhmann et al., 2011; Devaux et al., 2013) . The MV-V protein is known to specifically bind Mda5 (Andrejeva et al., 2004) . In our accompanying paper, we show that MV-V protein, once synthesized, affects Mda5 dephosphorylation after MV infection (Davis et al., 2014) . Thus, MV targets DC-SIGN early in infection to inhibit both RIG-I and Mda5 dephosphorylation, whereas later in infection, newly synthesized V protein prevents Mda5, but not RIG-I late during infection (Davis et al., 2014) . Because of positive feedback in the RLR pathway (Hou et al., 2011) , it is tempting to speculate that DC-SIGN-mediated antiviral suppression, which does not involve viral replication, is required to suppress both RIG-I and Mda5 to enable replication initiation in DCs, after which MV-V protein contributes further to antiviral suppression by blocking Mda5 activation. These data further indicate that PP1 phosphatases are important targets for MV to control RLRs and thereby type I IFN responses. Crosstalk between signaling pathways of different PRRs, such as DC-SIGN and TLRs, is crucial for induction of pathogen-specific cytokine profiles (Gringhuis et al., 2007 (Gringhuis et al., , 2009b . We have previously shown that activation of Raf-1 via DC-SIGN modulates NF-kB activity, affecting adaptive responses (Gringhuis et al., 2007) . Moreover, we have shown that DC-SIGN-Raf-1 signaling to NF-kB is exploited by HIV-1 for its replication in DCs (Gringhuis et al., 2010) . Here we show that MV requires Raf-1 signaling to inhibit dephosphorylation of both RIG-I and Mda5 to escape antiviral responses. Although Raf-1 signaling also induces acetylation of NF-kB (Gringhuis et al., 2007 (Gringhuis et al., , 2009b , we did not observe a role for NF-kB acetylation in the inhibition of type I IFN responses by MV (data not shown).
Raf-1 has a central role in DC-SIGN-mediated suppression of antiviral responses; we observed both increased RLR activation and type I IFN expression as well as reduced infection of DCs after Raf-1 inhibition. Raf-1 has been implicated in type I IFN expression and viral replication previously (Battcock et al., 2006; Pleschka et al., 2001; Zhang et al., 2012) ; however, here we report a DC-SIGN-dependent effect of the kinase. A role for DC-SIGN in promotion of MV replication via attachment has been shown earlier (de Witte et al., 2008; Mesman et al., 2012) . MV thus seems to target DC-SIGN to promote infection via multiple mechanisms, indicating a pivotal role for the receptor in viral infections. DC-SIGN functions as an attachment receptor for many viruses, such as HIV-1, hepatitis C virus, and dengue virus (Geijtenbeek et al., 2009) , and some of these viruses might also use DC-SIGN to target phosphatases to decrease virus-induced RLR activation and as such evade antiviral responses (Wies et al., 2013) . Indeed, mannose-expressing viruses that interact with DC-SIGN induce Raf-1 activation (Gringhuis et al., 2007) , suggesting that PP1 suppression is not restricted to MV. Moreover, since Raf-1 can be activated by other C-type lectin receptors (Gringhuis et al., 2009b) , Raf-1 signaling to decrease type I IFN responses could be a more general evasion strategy, not limited to DC-SIGN + DCs, but could also occur in other cells via other C-type lectin receptors. These data strongly indicate that PP1 phosphatases are targets for viruses to evade antiviral immunity, and preventing suppression of phosphatase activity by viruses might be a strategy to combat viral infections. Our study reveals that MV modulates antiviral responses at the level of RLR activation by blocking PP1 activity and highlights the role of DC-SIGN in viral infections.
EXPERIMENTAL PROCEDURES Cells and Ethics Statement
Peripheral blood monocytes were isolated from buffy coats of healthy donors (Sanquin) by consecutive Lymphoprep (Axis-Shield) and Percoll (Amersham Biosciences) gradient steps. Immature monocyte-derived DCs were cultured for 6-7 days from monocytes, in the presence of IL-4 and GM-CSF (500 and 800 U/ml, respectively; Invitrogen). DCs were cultured in RPMI supplemented with 10% fetal calf serum, penicillin/streptomycin (10 U/ml and 10 mg/ml, respectively; Invitrogen), and 2 mM L-glutamine (Lonza).This study was done in accordance with the ethical guidelines of the Academic Medical Center.
Broncho alveolar lavage (BAL) cells from MV-seronegative cynomolgus macaques (Macaca fascicularis) had been collected as prevaccination control samples during a previous study (de Swart et al., 2006) (Lackey et al., 2000) (1 mM; Sigma), guanabenz acetate salt (Tsaytler et al., 2011) (5-50 nM; Sigma), anti-DC-SIGN (20 mg/ml; AZN-D1), or anti-CD150 (20 mg/ml; MCA2251XZ; SBD Serotec). Cells were cocultured with Z-D-Phe-Phe-Gly-OH FIP (0.2 mM; Bachem) or recombinant neutralizing soluble IFNAR (B18R; eBioscience).
DCs were transfected with 25 nM siRNA using transfection reagent DF4 (Dharmacon) as described (Gringhuis et al., 2009b) . SMARTpool siRNAs used were RIG-I (M-012511-01), Mda5 (M-013041-00), TBK1 (M-003788-02), IKKε (M-003723-02), Raf-1 (M-003601-02), GADD34 (M-004442-01), I-1 (M-017092-01), and nontargeting siRNA (D-001206-13) as a control (Dharmacon). Silencing of expression was verified by real-time PCR and flow cytometry (Figures 3 and S1 ). Raf-1 expression was determined with anti-Raf-1 (9422; Cell Signaling Technology).
Viruses and Infection Assay rMV KS EGFP(3) and rMV IC323 EGFP(1) (Hashimoto et al., 2002) were passaged maximally three times in human Epstein-Barr virus-transformed B-lymphoblastic cell lines (B-LCL) or VERO/hCD150 cells to prevent attenuation. The titer was determined by titration on VERO/hCD150 cells, and the multiplicity of infection (moi) of each experiment was calculated based on this titer. DCs were infected with MV at an moi of 1, unless stated otherwise. Infection was determined after 24 or 48 hr; cells were fixed in 4% (w/v) paraformaldehyde, and EGFP levels were determined by flow cytometry.
Quantitative Real-Time PCR mRNA was isolated using mRNA capture kit (Roche). For detection of MV-N mRNA, cells were extensively washed before lysis. Detection of MV-N represents viral replication, as only mRNA, but no viral RNA, is isolated by mRNA capture kit. cDNA was synthesized with reverse transcriptase kit (Promega). PCR amplification was performed in the presence of SYBR Green in an ABI 7500 Fast PCR detection system (Applied Biosystems). Expression of target genes was normalized for GAPDH transcription with N t = 2 Ct (GAPDH)-Ct (target) .
Primers (Table S1 ) were designed using Primer Express (Applied Biosystems), except for MV-N primers.
Protein Phosphorylation
Phosphorylation of RIG-I, Mda5, TBK1, IKKε, and Raf-1 was detected by flow cytometry and analyzed on a FACS Calibur. Cells were first fixed in 3% paraformaldehyde for 10 min and permeabilized in 90% methanol at 4 C for 30 min. Primary antibody incubation with phospho-RIG-I(S8) (PAB15905; Abnova), phospho-RIG-I(T170) (PAB15906; Abnova), phosphoMda5(S88) (Wies et al., 2013) , phospho-c-raf(Ser338) (9427S; Cell Signaling Technology), c-raf(pTyr340/341) (553009; Calbiochem), phospho-TBK1/ NAK(Ser172) (5483S; Cell Signaling Technology), and phospho-IKK-epsilon(Ser172) (06-1340; Millipore) was followed by incubation with PE-conjugated anti-rabbit (711-116-152; Jackson ImmunoResearch).
Phosphorylated RIG-I and Mda5 were also detected by immunoblotting. Whole-cell extracts were prepared using RIPA lysis buffer (Cell Signaling Technology), and proteins were resolved by SDS-PAGE and detected with phospho-RIG-I(S8), phospho-RIG-I(T170), and phospho-Mda5(S88). Membranes were also probed with anti-b-actin (sc-81178; Santa Cruz) to ensure equal protein loading. Primary antibody incubation was followed by incubation with HRP-conjugated secondary antibody (rabbit: 21230, Pierce or mouse: P0161, DAKO) and ECL detection (Pierce).
IRF3 Cellular Localization
Nuclear and cytoplasmic extracts were prepared using NucBuster protein extraction kit (Novagen). Proteins were resolved by SDS-PAGE and detected by immunoblotting with anti-iRF3 (sc-9082; Santa Cruz). Membranes were also probed with anti-RNAPII (clone CTD4H8; Millipore) or anti-b-actin to ensure equal protein loading among cytoplasmic and nuclear extracts, respectively. Detection was done as described above. IRF3 was also detected by ELISA (USCN Life Sciences).
I-1 Phosphorylation and Association with PP1
I-1 was immunoprecipitated from 40 mg of extract with anti-PP1 inhibitor (ab40877; Abcam) on protein A/G-PLUS agarose beads (Santa Cruz) before immunocomplexes were resolved by SDS-PAGE, and phosphorylation of I-1 or I-1-associated PP1 proteins were detected by immunoblotting with antiphosphoserine (ab9332; Abcam), anti-phosphothreonine (9381; Cell Signaling Technology), anti-PP1alpha (2582; Cell Signaling Technology), or antiPP1Cgamma (ab169976; Abcam). Detection was done as described above.
PP1 Phosphatase Activity
Whole-cell lysates were prepared using lysis buffer (50 mM HEPES [pH 7.4], 10% glycerol, 1% Triton X-100, supplemented with protease inhibitors). PP1 activity in lysates was measured using ProFluor Ser/Thr PPase assay (Promega) in the presence of 4 mM okadaic acid to block PP2 activity. GADD34-PP1 specific activity in lysates was measured after capturing GADD34 in anti-GADD34 (ab131402; Abcam)-coated black-walled high-binding 96-well plates. The detected R110 fluorescence is a measure for PP1 activity.
Statistical Analysis
Statistical analyses were performed using the Student's t test for paired observations. Statistical significance was set at p < 0.05.
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